Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 178-180

  Peleman, R A ^a   Van De Velde, V ^a   Germonpre P R ^a   Fleurinck, C ^a   Rosseel, M T ^b   Pauwels, R A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TROVAFLOXACIN;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG PENETRATION; FEMALE; HUMAN; LUNG FLUID; LUNG LAVAGE; MALE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA;

EID: 0033989898     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.178-180.2000     Document Type: Article

References (13)

1. Alghasham, A. A., and M. C. Nahata. 1999. Trovafloxacin: a new fluoroquinolone. Ann. Pharmacother. 33:48-60.
2. Andrews, J. M., D. Honeybourne, N. P. Brenwald, D. Bannerjee, M. Iredale, B. Cunningham, and R. Wise. 1997. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibreoptic bronchoscopy. J. Antimicrob. Chemother. 39:797-802.
3. Ball, P. 1995. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108:43S-52S.
4. Bartlett, J. G., R. F. Breiman, L. A. Mandell, and T. M. File. 1998. Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:811-839.
5. Eliopoulos, G. M., K. Klimm, T. Eliopoulos, M. J. Ferraro, and R. C. Moellering. 1993. In vitro activity of CP 99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
6. Fuchs, P. C., A. L. Barry, S. D. Brown, and D. L. Sewell. 1996. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 15:678-682.
7. Gooding, B. B., and R. N. Jones. 1993. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob. Agents Chemother. 37:349-353.
8. Kips, J. C., R. A. Peleman, and R. A. Pauwels. 1998. Methods of examining induced sputum: do differences matter? Eur. Respir. J. 11:529-533.
9. Ling, T. K. W., E. Y. M. Liu, and A. F. B. Cheng. 1999. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates. Chemotherapy 45:22-27.
10. Peleman, R. A., P. Rytilä, J. C. Kips, G. F. Joos, and R. A. Pauwels. 1999. The cellular composition of induced sputum in chronic obstructive pulmonary diseases. Eur. Respir. J. 13:839-843.
11. Rennard, S. I., G. Basset, D. Lecossier, K. M. O'Donnell, P. Pinkston, and P. G. Martin. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J. Appl. Physiol. 60:532-538.
12. Sprangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of CP 99,219 compared to those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
13. Teng, R., T. G. Tensfeldt, T. E. Liston, and G. Foulds. 1996. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. J. Chromatogr. 675: 53-59.